HZNP
ER. Ana, apúntate otra que se chiva antes a analistas y periodistas y luego suelta su press release
http://ir.horizon-pharma.com/news-releases/news-release-details/horizon-pharma-plc-reports-strong-first-quarter-2018-orphan-and
Q1 EPS of $0.03 misses by $0.04.
Revenue of $223.88M (+1.4% Y/Y) misses by $9.49M.
A bote pronto, lo más destacable además del guidance, la transformación que se va a producir este Q2. Aunque se sabía, aún no se había informado tan claramente
Increasing Full-Year 2018 Net Sales Guidance Range to $
1.170 Billion to $1.200 Billion
and
Adjusted EBITDA Guidance Range to $390 Million to $415 Million
Establishing New Operating Structure Effective in Second-Quarter 2018,
With Two Operating Segments: Orphan and Rheumatology; Primary Care